Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Malidi Ahamadi"'
Autor:
Kinjal Sanghavi, Jakob Ribbing, James A. Rogers, Mariam A. Ahmed, Mats O. Karlsson, Nick Holford, Estelle Chasseloup, Malidi Ahamadi, Kenneth G. Kowalski, Susan Cole, Essam Kerwash, Janet R. Wade, Chao Liu, Yaning Wang, Mirjam N. Trame, Hao Zhu, Justin J. Wilkins, for the ISoP Standards & Best Practices Committee
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 5, Pp 710-728 (2024)
Abstract Modeling the relationships between covariates and pharmacometric model parameters is a central feature of pharmacometric analyses. The information obtained from covariate modeling may be used for dose selection, dose individualization, or th
Externí odkaz:
https://doaj.org/article/480b15b1cc5a4b0f8e7434ed8c4d630f
Autor:
Po‐Wei Chen, Mats O. Karlsson, Sebastian Ueckert, Ari Pritchard‐Bell, Cheng‐Pang Hsu, Sandeep Dutta, Malidi Ahamadi
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1988-2000 (2023)
Abstract Erenumab is a fully human anti‐canonical calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. The Migraine‐Specific Quality‐of‐Life Questionnaire (MSQ) is a 14‐item patient‐reported out
Externí odkaz:
https://doaj.org/article/9612d46c23f444d0b99f937a4df1a826
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 2, Pp 250-260 (2023)
Abstract Talimogene Laherparepvec (T‐VEC) is a first‐in‐class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery. Biodistribution data from a phase II study was used to develop a viral kine
Externí odkaz:
https://doaj.org/article/d1b7ce925d2e4b18b4554c4442799b30
Autor:
Johannes Kast, Saeideh Nozohouri, Di Zhou, Marc R. Yago, Po‐Wei Chen, Malidi Ahamadi, Sandeep Dutta, Vijay V. Upreti
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 9, Pp 2057-2074 (2022)
Abstract Advances in immuno‐oncology have provided a variety of novel therapeutics that harness the innate immune system to identify and destroy neoplastic cells. It is noteworthy that acceptable safety profiles accompany the development of these t
Externí odkaz:
https://doaj.org/article/8506c62661e546e89357bc447bb8e20a
Autor:
Klaus Romero, Daniela Conrado, Jackson Burton, Timothy Nicholas, Vikram Sinha, Sreeraj Macha, Malidi Ahamadi, Jesse Cedarbaum, John Seibyl, Kenneth Marek, Peter Basseches, Derek Hill, Ed Somer, Jill Gallagher, David T. Dexter, Arthur Roach, Diane Stephenson, for the Critical Path for Parkinson's (CPP) Consortium, the Parkinson's Progression Markers Initiative (PPMI)
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 3, Pp 240-246 (2019)
The Critical Path for Parkinson's (CPP) Imaging Biomarker and Modeling and Simulation working groups aimed to achieve qualification opinion by the European Medicines Agency (EMA) Committee for Medical Products for Human Use (CHMP) for the use of base
Externí odkaz:
https://doaj.org/article/947d1d44d90d4ee39519d4068df35b29
Autor:
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies;
Externí odkaz:
https://doaj.org/article/182d21e5687543179e830a09e90b9fdf
Publikováno v:
CPT: pharmacometricssystems pharmacology.
Talimogene Laherparepvec (T-VEC) is a first in class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery. Biodistribution data from phase 2 study was used to develop a viral kinetics mechanistic m
Autor:
Caroline H. Williams-Gray, Diane Stephenson, Klaus Romero, Judith Anton, Ferdous Gheyas, Nathan J. Hanan, Jonas Weidemann, Minhua Yang, Malidi Ahamadi, Massimo Bani, Bob Stafford, Charles S. Venuto, Chao Chen, Vincent Thuillier, Ka Lai Yee, Gennaro Pagano, Monica Javidnia, Sreeraj Macha, Nitin Mehrotra, Vikram Sinha, Kenneth Marek, Yaming Hang, Hans Smit, Anne Pedata, Mussie Akalu, Babak Boroojerdi, David T. Dexter, Glenn T. Stebbins
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:508-518
Leucine-rich repeat kinase 2 (LRRK2) inhibitors are currently in clinical development as interventions to slow progression of Parkinson's disease (PD). Understanding the rate of progression in PD as measured by both motor and non-motor features is pa
Autor:
Romeo Maciuca, Rachael A Lawson, Timothy Nicholas, David T. Dexter, Malidi Ahamadi, Chao Chen, David J. Burn, Kenneth Marek, Minhua Yang, Klaus Romero, Bob Stafford, Sreeraj Macha, Julie A. Stone, Diane Stephenson, Jackson Burton, Daniela J. Conrado, Vikram Sinha, Hans Smit, Massimo Bani, Mussie Akalu, Jill Gallagher, Babak Boroojerdi, Jonas Weidemann, Charles S. Venuto
Publikováno v:
Clin Pharmacol Ther
A quantitative assessment of Parkinson’s disease (PD) progression is critical for optimizing clinical trials design. Disease progression model was developed using pooled data from the Progression Marker Initiative study and the Incidence of Cogniti
Publikováno v:
Journal of cardiovascular pharmacology. 79(4)
Omecamtiv mecarbil is a small molecule that has been shown to improve cardiac function in patients with heart failure (HF) with reduced ejection fraction and is currently being developed as an oral modified release tablet for subjects with chronic HF